- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05181839
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
An Observational, Prospective, European, Multicentre, Mixed Methods Study to Describe the Lived Experience of X-Linked Hypophosphatemia (XLH) for Adolescents at End of Skeletal Growth
Panoramica dello studio
Descrizione dettagliata
This an observational, prospective, European, multicentre, mixed methods study that will involve the integration of quantitative and qualitative data exploring the lived experience of burosumab-treated adolescents with XLH at the end of skeletal growth. The study will involve two observation periods around the confirmed date of end of skeletal growth (index date)
The purpose of this study is to describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth, with a focus on adolescent reported symptoms, activity duration and intensity, and wider burden, and to describe change over time for those who continue and discontinue burosumab at the end of skeletal growth. The study will also explore the experiences of carers at the time the adolescent reaches the end of skeletal growth.
The key objectives of this study are to:
- Describe the lived experience of adolescents with XLH who are being treated with burosumab within the 12 weeks prior to reaching the end of skeletal growth.
- Describe the lived experience of adolescents with XLH during the 26 weeks immediately after the end of skeletal growth, overall and according to whether they continue or discontinue burosumab treatment.
- Describe within-person changes in the lived experience of adolescents with XLH after reaching end of skeletal growth, in relation to their own pre-end of skeletal growth period.
- Explore the supportive care needs and burden on carers at the time the adolescent with XLH reaches end of skeletal growth.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Lille, Francia
- Reclutamento
- Centre Hospitalier Universitair de Lille
-
Lyon, Francia
- Reclutamento
- Hospices Civils de Lyon
-
Paris, Francia
- Reclutamento
- APHP Paris - Assistance Publique Hopitaux de Paris
-
-
-
-
-
Groningen, Olanda
- Reclutamento
- University Medical Center Groningen - Beatrix Children's Hospital
-
-
-
-
-
Birmingham, Regno Unito
- Reclutamento
- Birmingham Women's and Children's Hospital
-
Bristol, Regno Unito
- Reclutamento
- Bristol Royal
-
Liverpool, Regno Unito
- Reclutamento
- Alder Hay Children's Hospital
-
London, Regno Unito
- Reclutamento
- Great Ormond Street Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Confirmed diagnosis of XLH (documented diagnosis of XLH in medical records, and evidence of at least one of the following: hypophosphataemia and/or impaired phosphate reabsorption due to elevated FGF23; PHEX mutation).
- Aged 12 to 17 years at start of study.
- Has open growth plates at enrolment and is estimated by their treating clinician to reach end of skeletal growth within the next 26 weeks (based on clinician's judgement in accordance with their normal approach used in routine practice).
- Has been receiving treatment with burosumab for at least study le (52 weeks).
- Provides informed consent to take part in the study (or provides assent, and carer provides consent, where applicable in accordance with specific country regulations).
Carer Inclusion Criteria:
- A main carer of a study participant (i.e. a parent or guardian who provides day-today support or care for the adolescent with XLH who is taking part in this study).
- Provides informed consent to take part in the study (for self and/or on behalf of eligible adolescent, where applicable in accordance with specific country regulations).
Exclusion Criteria:
- Unwilling and unable to participate in all aspects of the study (i.e. interviews, app, EQ- 5D-Y, wearable data collection) and /or does not agree to the collection of data from medical records.
- Missed two or more injections of burosumab in the past 6 months.
- Is planned to have any surgery during the study period.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Prospettiva
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Describe the lived experience of adolescents with XLH who are being treated with burosumab within the 12 weeks prior to reaching the end of skeletal growth.
Lasso di tempo: 12 Weeks
|
Describe the lived experience of adolescents with XLH who are being treated with burosumab within the 12 weeks prior to reaching the end of skeletal growth.
|
12 Weeks
|
Describe the lived experience of adolescents with XLH during the 26 weeks immediately after the end of skeletal growth, overall and according to whether they continue or discontinue burosumab treatment.
Lasso di tempo: 26 weeks
|
Describe the lived experience of adolescents with XLH during the 26 weeks immediately after the end of skeletal growth, overall and according to whether they continue or discontinue burosumab treatment.
|
26 weeks
|
Describe within-person changes in the lived experience of adolescents with XLH after reaching end of skeletal growth, in relation to their own pre-end of skeletal growth period.
Lasso di tempo: Up to 52 weeks
|
Describe within-person changes in the lived experience of adolescents with XLH after reaching end of skeletal growth, in relation to their own pre-end of skeletal growth period.
|
Up to 52 weeks
|
Explore the supportive care needs and burden on carers at the time the adolescent with XLH reaches end of skeletal growth.
Lasso di tempo: will be completed between weeks 21 and 25
|
Explore the supportive care needs and burden on carers at the time the adolescent with XLH reaches end of skeletal growth.
|
will be completed between weeks 21 and 25
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie metaboliche
- Malattie renali
- Malattie urologiche
- Disturbi della nutrizione
- Malattie genetiche, congenite
- Malattie muscoloscheletriche
- Avitaminosi
- Malattie da carenza
- Malnutrizione
- Malattie ossee
- Metabolismo, errori congeniti
- Malattie ossee, metaboliche
- Trasporto tubolare renale, errori congeniti
- Disturbi del metabolismo del calcio
- Metabolismo dei metalli, errori congeniti
- Disturbi del metabolismo del fosforo
- Rachitismo
- Carenza di vitamina D
- Rachitismo, ipofosfatemico
- Ipofosfatemia, familiare
- Rachitismo ipofosfatemico familiare
- Ipofosfatemia
Altri numeri di identificazione dello studio
- 2020-70-EU-CRY
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Ipofosfatemia legata all'X
-
Markus KnuppMerian Iselin Klinik; Basel Academy for Quality and Research in MedicineReclutamento
-
Joint Authority for Päijät-Häme Social and Health...Tampere UniversityAttivo, non reclutante
-
University of California, DavisNational Institute of Mental Health (NIMH)CompletatoPremutazione X FragileStati Uniti
-
GE HealthcareCompletato
-
Central Hospital, Nancy, FranceNon ancora reclutamentoOgni intervento endoscopico utilizzando i raggi XFrancia
-
Alko Do Brasil Industria e Comercio LtdaSconosciutoEsami a raggi X del tratto gastrointestinale
-
Ramsay Générale de SantéDr Béatrice DaoudSconosciutoRaggi X di latta | Parenchima polmonareFrancia
-
The Catholic University of KoreaCompletatoSindrome metabolica X | Sindrome cardiovascolare metabolica | Sindrome da insulino-resistenza X | Sindrome dismetabolica XCorea, Repubblica di
-
Assuta Medical CenterCompletatoRaggi X; Effetti | Complicazioni delle procedure bariatricheIsraele
-
University Hospital, BrestCompletatoMisura della dose di raggi XFrancia
Prove cliniche su Burosumab
-
Ultragenyx Pharmaceutical IncKyowa Kirin Co., Ltd.A disposizioneIpofosfatemia legata all'X | Osteomalacia indotta da tumore
-
Wuerzburg University HospitalKyowa Kirin, Inc.Completato
-
Redwood Dermatology SciencesUltragenyx Pharmaceutical IncCompletatoDolore, cronico | Ipofosfatemia | Rachitismo ipofosfatemicoStati Uniti
-
National Institute of Dental and Craniofacial Research...Attivo, non reclutanteDisplasia fibrosa dell'ossoStati Uniti
-
Bicetre HospitalSconosciutoMalattie Rare | Ipofosfatemia legata all'XFrancia
-
Laura TosiChildren's National Research Institute; Ultragenyx Pharmaceutical IncAttivo, non reclutanteSindrome da ipofosfatemia scheletrica cutanea (CSHS) | Sindrome del nevo epidermicoStati Uniti
-
Kyowa Kirin Pharmaceutical Development LtdCompletatoIpofosfatemia legata all'XRegno Unito, Francia, Irlanda, Italia
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletatoIpofosfatemia legata all'XStati Uniti
-
Kyowa Kirin Pharmaceutical Development LtdAttivo, non reclutanteIpofosfatemia legata all'X (XLH)Svezia, Spagna, Regno Unito, Italia, Austria, Francia
-
Kyowa Kirin Co., Ltd.Attivo, non reclutanteOsteomalacia indotta da tumore (TIO)Cina